Anti-Rheumatic Drugs - Finland

Finland

The Anti-Rheumatic Drugs market in Finland is expected to achieve a revenue of US$52.44m in 2024.
Furthermore, it is projected to exhibit a compound annual growth rate (CAGR 2024-2029) of 0.38%, leading to a market volume of US$53.45m by 2029.
In terms of global comparison, United States is anticipated to generate the highest revenue, amounting to US$34,700.00m in 2024.
Finland's pharmaceutical market for anti-rheumatic drugs is witnessing a surge in demand due to its aging population and high prevalence of rheumatoid arthritis.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Finland has been experiencing a steady growth in recent years.

Customer preferences: Finnish customers have been showing a growing interest in anti-rheumatic drugs due to the high prevalence of rheumatoid arthritis in the country. There has also been an increase in the aging population, which is more susceptible to rheumatic conditions. Additionally, the growing awareness about the benefits of early diagnosis and treatment of rheumatoid arthritis has further boosted the demand for anti-rheumatic drugs.

Trends in the market: One of the major trends in the Finnish Anti-Rheumatic Drugs market is the shift towards biologic drugs. Biologic drugs have been gaining popularity due to their higher efficacy and lower side effects compared to traditional disease-modifying anti-rheumatic drugs (DMARDs). This trend is expected to continue in the coming years as more biologic drugs are developed and approved for use in Finland.Another trend in the market is the increasing use of combination therapies. Combination therapies involve the use of two or more drugs to achieve better disease control and improve patient outcomes. This trend is driven by the need to achieve remission in patients with severe rheumatoid arthritis and reduce the risk of joint damage and disability.

Local special circumstances: Finland has a well-established healthcare system that provides universal coverage to all citizens. The government heavily subsidizes the cost of anti-rheumatic drugs, making them affordable for all patients. This has led to a high level of access to anti-rheumatic drugs, which has contributed to the growth of the market.

Underlying macroeconomic factors: The Finnish economy has been growing steadily in recent years, which has led to an increase in healthcare spending. The government has been investing heavily in healthcare infrastructure and services, which has improved access to healthcare for all citizens. This has contributed to the growth of the Anti-Rheumatic Drugs market in Finland.In conclusion, the Finnish Anti-Rheumatic Drugs market is expected to continue to grow in the coming years, driven by the high prevalence of rheumatoid arthritis, the aging population, and the growing awareness about the benefits of early diagnosis and treatment. The shift towards biologic drugs and combination therapies is expected to continue, and the government's commitment to universal healthcare coverage and investment in healthcare infrastructure will continue to support the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.